Current MNKD stock price forecast anticipates a potential rebound toward $5.30 if positive clinical updates emerge by Q Losing money on investments is something no shareholder enjoys, least of all institutional investors who saw their holdings value drop by 7.6% last week. However, the 9.7% one-year return to shareholders might have softened the blow. But they would probably be wary of future losses. According to Spark, TipRanksâ AI Analyst, MNKD is a Neutral. Market participants are watching FDA feedback on new delivery systems, which could shift valuation models. Options activity shows increased put volume this week, signaling some hedging against biotech volatility. MACD indicators are approaching a bullish crossover level.